Chen: A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) [HCQ]

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Chen et al., J. Zhejiang University (Med Sci), doi:10.3785/j.issn.1008-9292.2020.03.03

Chen et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J. Zhejiang University (Med Sci), doi:10.3785/j.issn.1008-9292.2020.03.03

Mar 2020 Source PDF

Twitter
Facebook

All Studies Meta

30 moderate hospitalized cases, all recovered. Time to RNA negative comparable. Less frequent radiological progression with HCQ but not statistically significant. One HCQ patient developed to a severe case. Treatment group 4 years older and with higher incidence of hypertension.

Important missing comments or errors? Let us know.

risk of radiological progression, 29.0% lower, RR 0.71, p = 0.57, treatment 5 of 15 (33.3%), control 7 of 15 (46.7%), NNT 7.5.

risk of viral+ at day 7, 100% higher, RR 2.00, p = 1.00, treatment 2 of 15 (13.3%), control 1 of 15 (6.7%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chen et al., 6 Mar 2020, Randomized Controlled Trial, China, peer-reviewed, 14 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit